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S U M M A R Y
Background: Raoultella ornithinolytica is known to inhabit aquatic environments. The clinical features and
outcomes of human infections caused by R. ornithinolytica have been reported for only a limited number
of cases.
Methods: A retrospective study of cases of infection caused by R. ornithinolytica managed at four
university hospital centres during the period before and after the introduction of matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) was performed. The aim was
to describe the clinical and microbiological characteristics, treatments, and outcomes.
Results: Among 187 R. ornithinolytica isolates identiﬁed for which clinical information was available,
71 were considered colonizers and 116 were pathogenic. A total of 112 cases of R. ornithinolytica
infection were identiﬁed. Urinary tract infections, gastrointestinal infections, wound and skin infections,
and bacteraemia were observed in 36%, 14%, 13%, and 5% of cases, respectively. Associated infections that
have been poorly reported, such as respiratory infections, i.e. pneumonia and pleural effusion, were
observed in 24% of cases. Additional diseases reported here for the ﬁrst time included osteomyelitis,
meningitis, cerebral abscess, mediastinitis, pericarditis, conjunctivitis, and otitis. The proportion of R.
ornithinolytica isolates resistant to antibiotics was found to be relatively high: 4% of isolates were
resistant to ceftriaxone, 6% to quinolones, and 13% to co-trimoxazole. The mortality rate related to
infection was 5%.
Conclusions: R. ornithinolytica is an underreported, emerging hospital-acquired infection and is
particularly associated with invasive procedures. R. ornithinolytica should never be considered simply
a saprophytic bacterium that occasionally contaminates bronchial lavage or other deep respiratory
samples or surgical sites. Physicians should be aware of the high rates of antimicrobial resistance of R.
ornithinolytica isolates so that immediate broad-spectrum antibiotic treatment can be established before
accurate microbiological results are obtained.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Raoultella ornithinolytica is an encapsulated Gram-negative
aerobic bacillus belonging to the Enterobacteriaceae family.
Formerly known as Klebsiella ornithinolytica, the bacterium was
reclassiﬁed as Raoultella based on new genetic approaches.1 R.
ornithinolytica is known to inhabit aquatic environments and can
be found in hospital environments.2 The pathogenic potential of R.
ornithinolytica isolates in human disease has become increasingly
important. Many cases of biliary tract infection, urinary infection,
and bacteraemia caused by R. ornithinolytica have been reported.3–
8 However, the clinical features, antimicrobial susceptibility, and
clinical outcomes of R. ornithinolytica infection have not yet been
well elucidated.
R. ornithinolytica infections in humans may be underestimated
because the bacterium is difﬁcult to identify using phenotypic
methods.9 The speed and the identiﬁcation rate of classic and rare
bacterial species involved in human infection have increased
signiﬁcantly since the arrival of matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) in
the authors’ centres.10 Recently, MALDI-TOF MS has been used
successfully in the differentiation of R. ornithinolytica from
Klebsiella oxytoca.11,12
The aim of this study was to describe the clinical and biological
characteristics and clinical outcomes of human infections caused
by R. ornithinolytica managed in the authors’ centres during the
period before and after the introduction of MALDI-TOF MS. This
study was presented as a poster at the 25th European Congress of
Clinical Microbiology and Infectious Diseases, Copenhagen,
Denmark (ECCMID 2015).
2. Materials and methods
A retrospective study of R. ornithinolytica infection cases
managed at four university hospital centres in southern France
(4000 beds) between January 1, 2002 and December 31, 2013 was
performed. This study was approved by the institutional research
ethics boards. From January 1, 2002 to August 30, 2009, R.
ornithinolytica isolates were identiﬁed using phenotypic methods,
i.e. semi-automated Gram staining (Aerospray Wiescor; Elitech)
and the Vitek 2 system (BioMe´rieux), with 330 microorganism
strains as references. Correct identiﬁcation of R. ornithinolytica was
determined in the presence of a T index 0.25. The identity of all of
the R. ornithinolytica isolates was conﬁrmed by 16S rRNA
molecular methods. From September 1, 2009 to December 31,
2013, R. ornithinolytica isolates were identiﬁed exclusively with
MALDI-TOF MS, as described previously.10
The antibiotic susceptibilities of R. ornithinolytica isolates were
determined and interpreted in accordance with the recommenda-
tions of the French Society for Microbiology and the European
Committee on Antimicrobial Susceptibility Testing (http://www.
sfm-microbiologie.org/UserFiles/ﬁles/casfm/
CASFM_EUCAST_V1_0_2014.pdf). In brief, R. ornithinolytica iso-
lates were susceptible to amoxicillin, amoxicillin–clavulanic acid,
ticarcillin–clavulanic acid, ceftriaxone, ciproﬂoxacin, oﬂoxacin,
and co-trimoxazole when the minimum inhibitory concentration
(MIC) breakpoint was 8 mg/l, 8 mg/l, 8 mg/l, 1 mg/l,
0.5 mg/l, 0.5 mg/l, and 2 mg/l, respectively. R. ornithinolytica
isolates were considered resistant to amoxicillin, amoxicillin–
clavulanic acid, ticarcillin–clavulanic acid, ceftriaxone, ciproﬂoxa-
cin, oﬂoxacin, and co-trimoxazole when the MIC breakpoint was
>8 mg/l, >8 mg/l, >16 mg/l, >2 mg/l, >1 mg/l, >1 mg/l, and
>4 mg/l, respectively. The same MIC breakpoints were used to
interpret antibiotic susceptibility during the study period.
The clinical features, treatments, and clinical outcomes were
recorded. Hospital-acquired infections were deﬁned as thoseoccurring within 48 h of hospital admission, 3 days of discharge, or
30 days following an operation, with additional criteria such as
immunosuppression, active or metastatic cancer, previous radia-
tion therapy, transfer from another care facility, elderly or
physically disabled person needing healthcare, previous invasive
procedures, surgery performed in the last 180 days, family member
with a multidrug-resistant microorganism, and recent treatment
with antibiotics, as reported recently by Cardoso et al.13 Only cases
presenting clinical symptoms with a positive culture from
bloodstream, urine, trans-bronchial catheter aspiration, bronch-
oalveolar lavage, pulmonary biopsy, pleural ﬂuid, peritoneal ﬂuid,
bile, or intraperitoneal deep samples, surgical skin, osteo-articular,
or deep tissue samples, cerebrospinal ﬂuid, or pericardial ﬂuid
were included in this study. Positive cultures from sputum samples
were considered colonization and not included in respiratory tract
infection. Similarly, positive cultures from wound swabs were
considered colonization and not included in wound and skin
infection.
Data analyses were performed using IBM SPSS Statistics
software version 20.0 (IBM Corp., Armonk, NY, USA). Proportions
were compared using the Chi-square test or Fisher’s exact two-
tailed test. A p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
Over the 91-month period from January 1, 2002 to August 30,
2009, a total of 121 R. ornithinolytica isolates were identiﬁed using
conventional phenotypic identiﬁcation methods and were con-
ﬁrmed by molecular identiﬁcation, i.e. 16 R. ornithinolytica isolates
per annum were identiﬁed among 22 692 bacteria isolates, the
equivalent of 7.05 R. ornithinolytica isolates/10 000 bacteria
isolates. Over the 52-month period from September 1, 2009 to
December 31, 2013, a total of 104 R. ornithinolytica isolates were
identiﬁed by MALDI-TOF MS, i.e. 24 R. ornithinolytica isolates per
annum were identiﬁed among 32 430 bacteria isolates, the
equivalent of 7.40 R. ornithinolytica isolates/10 000 bacteria
isolates (Figure 1). Among 225 R. ornithinolytica isolates identiﬁed
in the laboratory, 187 had available clinical information; 38 cul-
ture-positive samples of R. ornithinolytica isolates were excluded
due to uncertain clinical relevance. Seventy-one R. ornithinolytica
isolates were considered colonizers and were excluded from the
cases of R. ornithinolytica infection (Table 1).
A total of 112 patients with R. ornithinolytica infection
(116 culture-positive samples) were included in this review. The
median age of the patients was 66 years (range 1–98 years) and the
male to female sex ratio was 0.9. Sixty-one cases (54%) had
comorbidities, including solid cancer in 28 cases (25%), immuno-
deﬁciency in 28 cases (25%), and diabetes mellitus in 25 cases
(22%) (Table 2). Furthermore, 54 cases (48%) had undergone
invasive procedures, involving urinary catheters in 34 cases (30%),
mechanical ventilation in 16 cases (14%), and port catheters in four
cases (4%). Community-acquired infections caused by R. ornithi-
nolytica were observed in 57 cases (51%) and hospital-acquired
infections were observed in 55 cases (49%). Five patients had more
than two sites of hospital-acquired infection (Table 3).
With regard to the clinical symptoms, fever was observed in
45 cases (40%) and septic shock in six cases (5%) (Table 2). The main
type of infection was urinary tract infection, which was observed in
36 cases (32%). This was followed by respiratory infection in
27 cases (24%), gastrointestinal infection in 16 cases (14%), and
skin/wound infection in 15 cases (13%). Bacteraemia was found in
six cases (5%), including two cases of primary bacteraemia with no
discernible focus of infection, two cases of bacteraemia associated
with cholangitis, one case with appendicular peritonitis, and one
case with pneumonia. Bone and joint infections were observed in
Figure 1. Number of Raoultella ornithinolytica isolates identiﬁed and Raoultella ornithinolytica infection cases in the laboratory.
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observed in two cases. Other infection cases are detailed in Table 3.
R. ornithinolytica pneumonia was observed in 20 cases in this
study. Half of these cases were hospital-acquired pneumonia and
three were ventilator-associated pneumonia. Pleural effusion was
observed in seven cases, including ﬁve cases of hospital-acquired
pleural effusion and two cases of community-acquired pleural
effusion. The median age of patients with a respiratory infection in
this study was 65 years, and the male to female sex ratio in these
cases was 2. In eight cases, the patients presented a medical historyTable 1
Distribution of the sources of the clinical samples of Raoultella ornithinolytica isolates i
Source of clinical sample All 225 R. ornithinolytica isolates
(identiﬁed during the study
period)
116 
isola
case
Urine 95 36 
Respiratory sample 58 31 
Sputum 16 0 
Trans-bronchial catheter aspiration 27 20 
Pulmonary biopsy 2 1 
Bronchoalveolar lavage 6 3 
Pleural ﬂuid 7 7 
Bloodstream 18 7 
Deep sample 20 20 
Peritoneal ﬂuid 4 4 
Bile 2 2 
Pericardial effusion 1 1 
Skin and wound sample 24 15 
Wound swab 9 0 
Surgical skin biopsy 15 15 
Milk 1 0 
Conjunctiva of newborn 1 0 
Strain identiﬁcation (out of laboratory) 1 0 of solid cancer, including three cases of lung cancer. Nine patients
with a respiratory infection presented an immunodeﬁciency; this
involved chemotherapy and radiotherapy in three cases, cortico-
steroid treatment in three cases, organ transplants in two cases,
cirrhosis of the liver in one case, and rheumatoid arthritis in one
case. Five patients had diabetes mellitus and four patients were
chronic alcoholics.
R. ornithinolytica meningitis was observed in three cases,
including one case of peritoneal ventricular shunt infection and
two cases of community-acquired meningitis after cranial trauma.dentiﬁed in the laboratory during the 12-year study period
R. ornithinolytica
tes from 112 infection
s
71 R. ornithinolytica
isolates from
colonized cases
38 R. ornithinolytica isolates
from ‘no clinical relevance’
cases
44 15
16 11
16 0
0 7
0 1
0 3
0 0
0 11
0 0
0 0
0 0
0 0
9 0
9 0
0 0
1 0
1 0
0 1
Table 2
Clinical and biological characteristics of Raoultella ornithinolytica infection cases in
this study
Number of case (%)
Sex
Male 53 (47%)
Female 59 (53%)
Comorbidities 60 (54%)
Diabetes mellitus 25 (22%)
Alcoholism 5 (4%)
Solid cancer 28 (25%)
Immunodeﬁciency 28 (25%)
Chemotherapy and radiation therapy 10 (9%)
Corticosteroid therapy 10 (9%)
Cirrhosis of the liver 4 (4%)
Rheumatoid arthritis 3 (3%)
Organ transplant 4 (4%)
Asplenia 1 (1%)
Invasive procedures that may introduce infection
Urinary catheter 34 (30%)
Mechanical ventilation 16 (14%)
Port catheter 4 (4%)
Origin of infection
Community-acquired 12 (11%)
Hospital-acquired 15 (13%)
Clinical and biological characteristics
Fever 45 (40%)
Chills 2 (2%)
Septic shock 6 (5%)
Bacteraemia 6 (5%)
Leukocytosis 40 (36%)
C-reactive protein 40 mg/ml 34 (30%)
Polymicrobial infection 19 (17%)
Table 3
Clinical relevance of the 125 Raoultella ornithinolytica infection cases, including the 11
Type of infection R. ornithinolytica infection
Number of cases (%)
Urinary tract infection 36 (32%) 
Cystitis 25 (22%) 
Prostatitis 8 (7%) 
Pyelonephritis 3 (3%) 
Renal cyst infection - 
Respiratory infection 27 (24%) 
Pneumonia 20 (18%) 
Pleural effusion 7 (6%) 
Gastrointestinal infection 16 (14%) 
Cholangitis 8 (7%) 
Pancreatitis 4 (4%) 
Peritonitis 4 (4%) 
Enterocolitis 1 (1%) 
Wound and skin infections 15 (13%) 
Cellulitis 13 (12%) 
Skin abscess 1 (1%) 
Breast abscess 1 (1%) 
Bacteraemia 6 (5%) 
Systemic infection - 
Purpura fulminans - 
Port catheter infection 4 (4%) 
Mediastinitis 2 (2%) 
Arterial catheter infection 1 (1%) 
Aortic bi-femoral prosthesis infection 1 (1%) 
Pericarditis 1 (1%) 
Bone and joint infection 4 (4%) 
Chronic osteitis without orthopaedic device 3 (3%) 
Tibia pandiaphysitis 1 (1%) 
Central nervous system infection 4 (4%) 
Meningitis 3 (3%) 
Cerebral abscess 1 (1%) 
Conjunctivitis 2 (2%) 
External otitis 2 (2%) 
a Five cases had more than two sites of hospital-acquired infection.
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trauma was observed in one case. The median age of patients with
a neurological infection was 76 years (range 24–83 years). One
patient with a neurological infection caused by R. ornithinolytica
had diabetes mellitus and one patient had pancreatic cancer.
Ninety-three cases (83%) of R. ornithinolytica infection were
monomicrobial and 19 cases (17%) were polymicrobial. The
polymicrobial infections included seven cases of pneumonia
hospitalized in intensive care (identiﬁed from two bronchoalveolar
lavage samples and ﬁve trans-bronchial catheter aspirations), ﬁve
cases of cellulitis (documented by surgical skin biopsies), four
cases of peritonitis (documented in peritoneal ﬂuid), two cases of
chronic osteitis, and one case of pyelonephritis with a urinary
catheter-related infection. Twenty-nine bacteria were found to be
associated with the R. ornithinolytica infections: Escherichia coli
(eight cases), Staphylococcus aureus (four cases), Staphylococcus
epidermidis (four cases), Pseudomonas aeruginosa (four cases),
Enterococcus faecalis (three cases), Enterobacter aerogenes (one
case), Morganella morganii (one case), Serratia marcescens one
case), Stenotrophomonas maltophilia (one case), Enterobacter
cloacae (one case), and Mycobacterium avium (one case). Ninety-
ﬁve percent of R. ornithinolytica isolates in this study were resistant
to amoxicillin, 16% to amoxicillin–clavulanic acid, 13% to
ticarcillin–clavulanic acid, 4% to ceftriaxone, 6% to quinolones,
1% to aminoglycoside, and 10% to co-trimoxazole. No case of
resistance to imipenem–cilastatin or extended-spectrum beta-
lactamases was observed in this study.
Eleven patients (10%) infected with R. ornithinolytica underwent
surgery, including a cholecystectomy in three cases (3%), abscess
drainage in two cases (2%), laparotomy in two cases (2%),
amputation in three cases (3%), osteosynthesis in one case (1%),2 cases in the present study and 23 cases reported in the literature
Hospital-acquired
infectiona
Number of cases (%)
Community-acquired
infection
Number of cases (%)
Number of cases
reported in the
literature
20 (18%) 16 (14%) 6
20 (18%) 5 (4%) 4
- 8 (7%) 1
- 3 (3%) -
- -
15 (13%) 12 (11%) -
10 (9%) 10 (9%) -
5 (4%) 2 (2%) -
6 (13%) 10 (8%) -
- 8 (7%) 9
2 (2%) 2 (2%) 1
3 (3%) 1 (1%) 1
1 (1%) - 2
8 (7%) 7 (6%) 2
7 (6.2%) 6 (5.4%) -
- 1 (1%) -
1 (1%) - -
3 (2.7%) 3 (2.7%) 16
- - 1
- - 1
4 (4%) - -
2 (2%) - -
1 (1%) - -
1 (1%) - -
1 (1%) - -
- 4 (4%) -
- 3 (3%) -
- 1 (1%) -
2 (2%) 2 (2%) -
1 (1%) 2 (2%) -
1 (1%) - -
1 (1%) 1 (1%) -
1 (1%) 1 (1%) -
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and ileostomy in one case (1%). The antibiotics most frequently
used were ceftriaxone (26% of cases), aminoside (24%), amoxicil-
lin–clavulanic acid (21%), quinolones (21%), piperacillin–tazobac-
tam (12%), and imipenem–cilastatin (11%). The mean duration of
treatment was 5  12 days (range 2–90 days). One hundred and
three of the patients (92%) were discharged. Nine patients (8%) died,
involving six cases of infection and three cases (3%) of cancer. No
comorbidity, risk factors, clinical features, or biological characteristics
associated with unfavourable cases was found on univariate analysis.
4. Discussion
This series of human infections caused by R. ornithinolytica
managed at four university hospital centres in France over the last
12 years is the largest reported to date. A literature search
identiﬁed 86 reported cases of R. ornithinolytica (formerly Klebsiella
ornithinolytica),3–8,14–27 and half of these cases were reported in
2015.10,12,24–26 A high rate of hospital-acquired infection was
observed in the present study (49%), which may be explained by
the high proportion of patients who had undergone invasive
procedures (48%) involving, for example, urinary catheters,
mechanical ventilation, and port catheters. Physicians should take
into consideration the fact that cases of R. ornithinolytica infection
acquired in hospital are poorly reported in the literature and
should adapt their management of infection control and preven-
tion accordingly.
Previously described comorbidities and risk factors reported
in the literature, such as solid cancer,3–5,21 post-urethra
trauma,20 and post-invasive procedures,14 were observed in
this study. Moreover, it was found that half of the patients had
diabetes mellitus, a solid cancer, or an immunodeﬁciency
(Table 2). Among the invasive procedures, the number of
infection cases involving urinary catheters was high (34 cases);
new infection cases involving mechanical ventilation and/or
port catheters were also observed. The relationship of R.
ornithinolytica infection with invasive procedures has not been
reported much in the literature.
As well as the well-known clinical presentations of R.
ornithinolytica infections, such as primary or cholangitis blood-
stream infection,3–5,7,14,16,18,20,22 catheter-related bloodstream
infection,8,26 biliary tract infection,3–5 urinary tract infection,5,15,21
and skin infection,19,20 cases of respiratory infection including
community- and hospital-acquired pneumonia and pleural effu-
sion were also identiﬁed in this study, and these have been poorly
reported. Boattini et al. recently reported three cases of communi-
ty-acquired pneumonia and three cases of hospital-acquired
pneumonia among 25 cases of R. ornithinolytica infection over a
5-year period in six university hospital centres in Lisbon.28 Of note,
infections that have not been reported previously were observed in
the present study, including pleural effusion, osteomyelitis,
meningitis, cerebral abscess, mediastinitis, pericarditis, conjuncti-
vitis, and otitis.
The proportion of R. ornithinolytica isolates with reduced
susceptibility to antibiotics was relatively high in this study and
in reported cases. The presence of a chromosomal bla gene is key to
the mechanism of beta-lactam resistance displayed by R.
ornithinolytica isolates.14,27,29,30 Resistance to ampicillin has been
reported in six cases.4,16,21 The combination of amino- and
carboxypenicillin with clavulanic acid makes R. ornithinolytica
environmental isolates susceptible to these molecules.29 Some
resistance to antibiotics such as ciproﬂoxacin (two cases) and co-
trimoxazole (one case) has been observed.21
Among the 86 isolates reported in the literature, 80% were
resistant to amoxicillin, 17% to amoxicillin–clavulanic acid, 10%
to third-generation cephalosporins, 12% to quinolones, 13% toco-trimoxazole, 15% to piperacillin–tazobactam, 7% to aminosides,
and 7% to carbapenems.3–8,14–27 Few of these studies reported
cases of R. ornithinolytica infection with isolates resistant to
multiple antibiotics, including KPC14 and NDM-1 strains.27 In this
study, the proportions of isolates resistant to ceftriaxone,
quinolones, and aminosides were a little bit lower than reported
in the literature (4%, 6%, and 1%, respectively). No isolate resistant
to carbapenems was observed in the present study. In the future,
screening of R. ornithinolytica clinical isolates for reduced
susceptibility to antibiotics will improve our understanding of
the mechanisms underlying increased antibiotic resistance.
Among the 69 reported cases, the mortality rate of human
infections caused by R. ornithinolytica was relatively high (20%).3–
6,8,14–20,22–26 This rate was particularly high in cases of bacteraemia
(34–44%).4,8,14,22,23,25,28 In the study cases, the mortality rate was
lower (9%) and included three patients (3%) who died of cancer and
six patients (6%) who died of septic shock related to pneumonia
(three cases), pleural effusion (one case), skin infection (one case),
and cholangitis (one case). This observation may be explained by
the low proportion of bacteraemia cases in the present study.
Cases of R. ornithinolytica are difﬁcult to distinguish from K.
oxytoca in clinical laboratories using routine phenotypic identiﬁ-
cation methods such as the Vitek 2 GN ID card (BioMe´rieux),
MicroScan Neg Combo 32 panel (Dade Behring), and API 20E test
kit (BioMe´rieux).9 The API 20E system (BioMe´rieux) and MicroScan
Neg Combo 32 panel (Dade Behring) had only one biochemical test
discriminating between R. ornithinolytica and K. oxytoca; these
needed to be completed by an ornithine decarboxylase (ODC) test.
The Vitek 2 system (BioMe´rieux) had ﬁve biochemical discrimi-
nating tests that can identify ODC-negative R. ornithinolytica
isolates, but this technique had to be conﬁrmed by molecular
identiﬁcation (16S rRNA gene sequencing) due to the lack of
speciﬁcity. Park et al. showed that some Enterobacteriaceae isolates
were identiﬁed as R. ornithinolytica by Vitek 2 (BioMe´rieux).9
Following the successful implementation of MALDI-TOF MS for
routine bacterial identiﬁcation in clinical microbiology laborato-
ries, this technique has been used to correctly identify R.
ornithinolytica isolates compared to 16S, rpoB gene sequencing.
In this study, the number of R. ornithinolytica isolate identiﬁca-
tions increased from 16 isolates to 24 isolates per annum following
the arrival of MALDI-TOF MS in the laboratory; this is proportional
to the increasing global number of bacterial identiﬁcations in that
laboratory. Since the introduction of MALDI-TOF MS, the identiﬁ-
cation of R. ornithinolytica isolates has become fast and reliable,
often without conﬁrmation by molecular procedures.
R. ornithinolytica is a Gram-negative aquatic–commensal of the
Enterobacteriaceae family that has occasionally been reported to
survive in human saliva.2,31 The bacterium has also been isolated
from human digestive organs in the authors’ laboratory (data not
published). R. ornithinolytica has become a human pathogen in
many community-acquired and/or hospital-acquired infections.
Compared with other Enterobacteriaceae, only a few virulence
factors have been recognized in R. ornithinolytica. The well-known
factors involved in the pathogenicity of R. ornithinolytica are (1) its
ability to adhere to human tissues, (2) its ability to convert
histidine to histamine in scombroid ﬁsh, thus causing redness and
ﬂushing of the skin, as suspected in the case of diabetic foot,19 and
(3) its ability to form bioﬁlms in urinary catheters.32 The ability to
colonize the inner surfaces of indwelling urinary catheters is a
major cause of hospital-acquired urinary tract infections. It is thus
thought that these mechanisms could play an important role in the
pathogenesis of infection. Other virulence factors, such as the
ability to form bioﬁlms, will help us to better understand the
relationship between R. ornithinolytica human infections and
invasive procedures such as the implantation of venous catheters,
intra-vascular prostheses, or orthopaedic devices.
P. Seng et al. / International Journal of Infectious Diseases 45 (2016) 65–7170In conclusion, R. ornithinolytica is a virulent pathogen of
community-acquired infections that has become an emerging
hospital-acquired infection, particularly after invasive procedures.
Cases of R. ornithinolytica infection have been underreported
because it is difﬁcult to identify by conventional phenotypic
methods. The epidemiology of R. ornithinolytica infections may
change with the arrival of MALDI-TOF MS, a very promising
technique for identiﬁcation. Physicians should consider the
increase in R. ornithinolytica isolates resistant to antibiotics and
the increase in medical and surgical device-associated R. ornithi-
nolytica infections; the removal of such devices may be needed to
control the infection.
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